PPARA and hyperlipidemia: A previous study showed that oral administration of the PPARα agonist fenofibrate, which is widely used to treat hyperlipidemia (Wierzbicki et al., 2003), prevented the progression of sciatic neuropathy in diabetic mice by activating of the AMPK-related signaling pathway (Cho et al., 2014).